ClinicalTrials.gg
CompletedNCT04693234Updated Apr 27, 2025Results posted

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

A Phase 2 interventional study of Tislelizumab and Ociperlimab in Cervical Cancer, sponsored by BeiGene. Completed at 68 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Enrollment
121st of 360
178 · median 90
Started
2021
with 51 others
Phase 2
137 of 455
71 open now
Registered
154th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 121st largest by enrollment of the 360 interventional ones that give a count, is one of 52 that started in 2021, is one of 137 in phase 2, and was the 154th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous treatments. The study included two groups and took place at multiple medical centers.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix.
  2. Progression on or after one or more for management of recurrent or disease and is not amenable to curative treatment (eg, systemic chemotherapy, surgery, or radiotherapy).
  3. as assessed by v1.1. Note: A lesion in an area subjected to prior loco-regional therapy, including previous radiotherapy, is not considered measurable unless there has been demonstrated progression in the lesion since the therapy as defined by RECIST v1.1.
  4. Participants must submit qualified (formalin-fixed paraffin-embedded block containing tumor [preferred] or approximately 15 [at least 6] unstained slides) with an associated pathology report, or agree to a tumor biopsy for determination of Programmed death-ligand 1 () expression and other biomarker analyses (fresh tumor biopsies are strongly recommended at baseline in participants with readily accessible tumor lesions and who consent to the biopsies).
  5. Participant must have adequate organ function as indicated by the screening laboratory values obtained within 7 days before the first study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Prior therapy with an , anti-PD-L1, anti-PD-L2, TIGIT or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
  2. Any active ≤ 2 years before first dose of study drug except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of breast).
  3. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within 2 weeks of intervention).
  4. Any major surgical procedure ≤ 28 days before first dose of study drug. Participants must have recovered adequately from the toxicity and/or complications from the intervention before the first dose of study drug.
  5. Has received any chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin, etc.) or any therapies within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug or has received palliative radiation treatment or other local regional therapies within 14 days before the first dose of study drug.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Cohort 1: Ociperlimab + Tislelizumab

    Tislelizumab 200 milligrams (mg) intravenously (IV) once every 3 weeks (Q3W) combined with ociperlimab (BGB-A1217) 900 mg IV Q3W

    Biological: Tislelizumab · Biological: Ociperlimab

  • Experimental
    Cohort 2: Tislelizumab

    Tislelizumab 200 mg IV Q3W monotherapy

    Biological: Tislelizumab

Interventions

  • BiologicalTislelizumab

    200 mg administered intravenously once every 3 weeks on day 1 of each cycle

    Also known as: BGB-A317, TEVIMBRA®

  • BiologicalOciperlimab

    900 mg administered intravenously once every 3 weeks on day 1 of each cycle

    Also known as: BGB-A1217

06

What researchers measure

Primary outcomes

  1. Cohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive Participants

    ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the IRC per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). PD-L1-positive refers to participants whose tumors had a PD-L1 TAP score ≥ 5%.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.

  2. Cohort 1: ORR Assessed by the IRC in All Treated Participants

    ORR is defined as the percentage of participants who had a confirmed CR or PR as assessed by the IRC per RECIST v1.1.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.

Secondary outcomes

  1. Cohort 2: Objective Response Rate (ORR) Assessed by an Independent Review Committee in All Treated Participants

    ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the IRC per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 10.40 months for Cohort 2.

  2. ORR Assessed by the Investigator in PD-L1-Positive Participants

    ORR is defined as the percentage of participants who had confirmed CR or PR as assessed by the investigator per RECIST v1.1 in the PD-L1 Score \>= 5% Safety Analysis Set.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  3. ORR as Assessed by the Investigator in All Treated Participants

    ORR is defined as the percentage of participants who had a confirmed CR or PR as assessed by the investigator per RECIST v1.1.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  4. Duration of Response (DOR) Assessed by the IRC

    DOR is defined as the time from the first confirmed objective response until the first documentation of progression or death, whichever occurred first, assessed by the IRC according to RECIST v1.1 in the Safety Analysis Set.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  5. Duration of Response (DOR) Assessed by the Investigator

    DOR is defined as the time from the first confirmed objective response until the first documentation of progression or death, whichever comes first, assessed by the investigator according to RECIST v1.1 in the Safety Analysis Set. Data was based on number of responders.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  6. Progression Free Survival (PFS)

    Defined as the time from the date of first dose of study drug to the date of first documentation of disease progression or death, whichever occurred first as assessed by both the IRC and the investigator's review per RECIST v1.1 in the Safety Analysis Set.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  7. Time to Response (TTR) Assessed by the IRC

    TTR is defined as the time from the date of first dose of study drug to the first documentation of response as assessed by the IRC per RECIST v1.1, in the Safety Analysis Set.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  8. Time to Response (TTR) Assessed by the Investigator

    TTR is defined as the time from the date of first dose of study drug to the first documentation of response as assessed by the investigator per RECIST v1.1, in the Safety Analysis Set.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  9. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who achieve CR, PR, or stable disease (SD) as assessed by both the IRC and investigator per RECIST v1.1 in the Safety Analysis Set.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  10. Clinical Benefit Rate (CBR)

    Defined as the percentage of participants who achieve CR, PR, or durable SD (SD ≥ 24 weeks) as assessed by both the IRC and investigator per RECIST v1.1 in the Safety Analysis Set.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  11. Overall Survival (OS)

    Overall survival is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.

    Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.

  12. Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life, Physical Functioning, and Pain Scores

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life.

    Time frame: Baseline to Cycles 3 and 5 ( Each cycle was 21 days)

  13. Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Index Score

    QLQ-CX24 is the cervical cancer module of the QLQ-C30. CX24 is comprised of 24 questions grouped into 3 symptom scales and 6 single symptom items. Each question is answered on a scale from 1 (not at all) to 4 (very much). The scales include Symptom Experience (11 items), Body Image (3 items) and Sexual/vaginal Functioning (4 items). The single symptom items include Lymphedema, Peripheral Neuropathy, Menopausal Symptoms, Sexual Worry, Sexual Activity and Sexual Enjoyment. Raw scores are transformed into a 0 to 100 scale via linear transformation. The Index score is calculated as the average of the 3 symptom scales and 6 single item scores. Lower scores indicate better HRQoL.

    Time frame: Baseline to Cycles 3 and 5 ( Each cycle was 21 days)

  14. Number of Participants Experiencing Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether considered related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement (eg, may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above).

    Time frame: From the first dose of study drug to 30 days after the last dose; maximum treatment exposure was 23.5 months.

  15. Serum Ociperlimab (BGB-A1217) Concentrations at Specified Timepoints

    The timepoints are defined as predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion).

    Time frame: Day 1 of Cycles 1, 2, 5, 9, and 17 (each cycle was 21 days)

  16. Serum Tislelizumab Concentrations at Specified Timepoints

    The timepoints are defined as predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion).

    Time frame: Day 1 of Cycles 1, 2, 5, 9, and 17 (each cycle is 21 days)

  17. Number of Participants Who Developed Positive Anti-drug Antibodies (ADAs) to Ociperlimab

    Number and percentage of participants who developed detectable ADAs to ociperlimab during the treatment period.

    Time frame: Samples for ADA analysis were collected predose on Day 1 of Cycles 1, 2, 5, 9 and 17, and at the Safety Follow-up Visit (30 days after last dose) up to the immunogenicity data cut-off date of June 1, 2023 (approximately 21 months).

  18. Number of Participants Who Developed Anti-drug Antibodies (ADAs) to Tislelizumab

    Number and percentage of participants who developed detectable ADAs during the treatment period.

    Time frame: Samples for ADA analysis were collected predose on Day 1 of Cycles 1, 2, 5, 9 and 17, and at the Safety Follow-up Visit (30 days after last dose), up to the immunogenicity data cut-off date of June 1, 2023 (approximately 21 months).

07

Results

Posted Apr 27, 2025

Participant flow

Participants were enrolled in multiple study centers in China, South Korea, and Europe.The first participant dosed was on March 3rd, 2021 and the last participant completed on August 31st, 2023.

Participant flow — Overall Study
MilestoneCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Started13840
Completed00
Not completed13840
Withdrew: Death7919
Withdrew: Sponsor ended study4718
Withdrew: Withdrawal by subject102
Withdrew: Lost to follow-up21

Outcome measures

PrimaryCohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive Participants

ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the IRC per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). PD-L1-positive refers to participants whose tumors had a PD-L1 TAP score ≥ 5%.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.
Reported as:
Number · percentage of participants
Cohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive Participants
percentage of participantsCohort 1: Ociperlimab + Tislelizumab
Cohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive Participants26.2 (17.2 to 36.9)
Statistical analysis
  • Cohort 1: Ociperlimab + Tislelizumab · Binomial Exact Test · p = 0.0054The p-value was calculated from the binomial exact test of tislelizumab combined with ociperlimab versus historical rate of 0.15.
PrimaryCohort 1: ORR Assessed by the IRC in All Treated Participants

ORR is defined as the percentage of participants who had a confirmed CR or PR as assessed by the IRC per RECIST v1.1.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.
Reported as:
Number · percentage of participants
Cohort 1: ORR Assessed by the IRC in All Treated Participants
percentage of participantsCohort 1: Ociperlimab + Tislelizumab
Cohort 1: ORR Assessed by the IRC in All Treated Participants22.5 (15.8 to 30.3)
Statistical analysis
  • Cohort 1: Ociperlimab + Tislelizumab · Binomial Exact Test · p = 0.0127The p-value was calculated from the binomial exact test of tislelizumab combined with ociperlimab versus historical rate of 0.15.
SecondaryCohort 2: Objective Response Rate (ORR) Assessed by an Independent Review Committee in All Treated Participants

ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the IRC per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 10.40 months for Cohort 2.
Reported as:
Number · percentage of participants
Cohort 2: Objective Response Rate (ORR) Assessed by an Independent Review Committee in All Treated Participants
percentage of participantsCohort 2: Tislelizumab
Cohort 2: Objective Response Rate (ORR) Assessed by an Independent Review Committee in All Treated Participants32.5 (18.6 to 49.1)
SecondaryORR Assessed by the Investigator in PD-L1-Positive Participants

ORR is defined as the percentage of participants who had confirmed CR or PR as assessed by the investigator per RECIST v1.1 in the PD-L1 Score \>= 5% Safety Analysis Set.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Number · percentage of participants
ORR Assessed by the Investigator in PD-L1-Positive Participants
percentage of participantsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
ORR Assessed by the Investigator in PD-L1-Positive Participants25.0 (16.2 to 35.6)30 (11.9 to 54.3)
SecondaryORR as Assessed by the Investigator in All Treated Participants

ORR is defined as the percentage of participants who had a confirmed CR or PR as assessed by the investigator per RECIST v1.1.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Number · percentage of participants
ORR as Assessed by the Investigator in All Treated Participants
percentage of participantsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
ORR as Assessed by the Investigator in All Treated Participants21.0 (14.5 to 28.8)22.5 (10.8 to 38.5)
SecondaryDuration of Response (DOR) Assessed by the IRC

DOR is defined as the time from the first confirmed objective response until the first documentation of progression or death, whichever occurred first, assessed by the IRC according to RECIST v1.1 in the Safety Analysis Set.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Median · Months
Duration of Response (DOR) Assessed by the IRC
MonthsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Duration of Response (DOR) Assessed by the IRCNA (5.6 to NA)NA (4.1 to NA)
SecondaryDuration of Response (DOR) Assessed by the Investigator

DOR is defined as the time from the first confirmed objective response until the first documentation of progression or death, whichever comes first, assessed by the investigator according to RECIST v1.1 in the Safety Analysis Set. Data was based on number of responders.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Median · Months
Duration of Response (DOR) Assessed by the Investigator
MonthsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Duration of Response (DOR) Assessed by the InvestigatorNA (5.5 to NA)NA (5.6 to NA)
SecondaryProgression Free Survival (PFS)

Defined as the time from the date of first dose of study drug to the date of first documentation of disease progression or death, whichever occurred first as assessed by both the IRC and the investigator's review per RECIST v1.1 in the Safety Analysis Set.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
IRC3.5 (2.6 to 4.9)5.7 (2.3 to 8.1)
Investigator3.9 (2.6 to 4.4)5.7 (2.6 to 9.2)
SecondaryTime to Response (TTR) Assessed by the IRC

TTR is defined as the time from the date of first dose of study drug to the first documentation of response as assessed by the IRC per RECIST v1.1, in the Safety Analysis Set.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Mean · Weeks
Time to Response (TTR) Assessed by the IRC
WeeksCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Time to Response (TTR) Assessed by the IRC9.02 ± 4.70411.78 ± 4.709
SecondaryTime to Response (TTR) Assessed by the Investigator

TTR is defined as the time from the date of first dose of study drug to the first documentation of response as assessed by the investigator per RECIST v1.1, in the Safety Analysis Set.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Mean · Weeks
Time to Response (TTR) Assessed by the Investigator
WeeksCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Time to Response (TTR) Assessed by the Investigator10.66 ± 3.0108.92 ± 3.174
SecondaryDisease Control Rate (DCR)

DCR is defined as the percentage of participants who achieve CR, PR, or stable disease (SD) as assessed by both the IRC and investigator per RECIST v1.1 in the Safety Analysis Set.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
IRC63.0 (54.4 to 71.1)67.5 (50.9 to 81.4)
Investigator62.3 (53.7 to 70.4)75.0 (58.8 to 87.3)
SecondaryClinical Benefit Rate (CBR)

Defined as the percentage of participants who achieve CR, PR, or durable SD (SD ≥ 24 weeks) as assessed by both the IRC and investigator per RECIST v1.1 in the Safety Analysis Set.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
IRC29.0 (21.6 to 37.3)50.0 (33.8 to 66.2)
Investigator31.2 (23.6 to 39.6)50.0 (33.8 to 66.2)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.

Time frame:
Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Reported as:
Median · Months
Overall Survival (OS)
MonthsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Overall Survival (OS)9.0 (8.1 to 10.4)NA (10.5 to NA)
SecondaryMean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life, Physical Functioning, and Pain Scores

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life.

Time frame:
Baseline to Cycles 3 and 5 ( Each cycle was 21 days)
Reported as:
Mean · Score on a scale
Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life, Physical Functioning, and Pain Scores
Score on a scaleCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
GHS/QoL: Baseline Score64.21 ± 20.82162.06 ± 22.402
GHS/QoL: Change from Baseline to Cycle 3 Day 10.37 ± 22.1585.30 ± 23.088
GHS/QoL: Change from Baseline to Cycle 5 Day 13.46 ± 18.3555.13 ± 21.995
Physical Functioning: Baseline Score78.91 ± 19.21176.67 ± 22.501
Physical Functioning: Change from Baseline at Cycle 3 Day 1-2.62 ± 16.5821.82 ± 18.876
Physical Functioning: Change from Baseline at Cycle 5 Day 10.00 ± 14.9275.38 ± 16.113
Pain: Baseline Score27.73 ± 28.07030.26 ± 27.084
Pain: Change from Baseline at Cycle 3 Day 1-2.08 ± 21.820-9.09 ± 26.051
Pain: Change from Baseline at Cycle 5 Day 1-2.16 ± 22.353-8.97 ± 24.599
SecondaryMean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Index Score

QLQ-CX24 is the cervical cancer module of the QLQ-C30. CX24 is comprised of 24 questions grouped into 3 symptom scales and 6 single symptom items. Each question is answered on a scale from 1 (not at all) to 4 (very much). The scales include Symptom Experience (11 items), Body Image (3 items) and Sexual/vaginal Functioning (4 items). The single symptom items include Lymphedema, Peripheral Neuropathy, Menopausal Symptoms, Sexual Worry, Sexual Activity and Sexual Enjoyment. Raw scores are transformed into a 0 to 100 scale via linear transformation. The Index score is calculated as the average of the 3 symptom scales and 6 single item scores. Lower scores indicate better HRQoL.

Time frame:
Baseline to Cycles 3 and 5 ( Each cycle was 21 days)
Reported as:
Mean · score on a scale
Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Index Score
score on a scaleCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Baseline Score30.86 ± 6.94231.43 ± 4.497
Change from Baseline at Cycle 3 Day 10.61 ± 5.915-0.71 ± 4.163
Change from Baseline at Cycle 5 Day 1-0.15 ± 5.7901.05 ± 4.227
SecondaryNumber of Participants Experiencing Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether considered related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement (eg, may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above).

Time frame:
From the first dose of study drug to 30 days after the last dose; maximum treatment exposure was 23.5 months.
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Number of Participants with at least one TEAE13539
Number of participants with at least one SAE6117
SecondarySerum Ociperlimab (BGB-A1217) Concentrations at Specified Timepoints

The timepoints are defined as predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion).

Time frame:
Day 1 of Cycles 1, 2, 5, 9, and 17 (each cycle was 21 days)
Reported as:
Geometric mean · μg/mL
Serum Ociperlimab (BGB-A1217) Concentrations at Specified Timepoints
μg/mLCohort 1 (Predose)Cohort 1 (Postdose)
Cycle 1 Day 10.00 ± NA363.19 ± 24.21
Cycle 2 Day 146.60 ± 46.98—
Cycle 5 Day 182.57 ± 55.30440.70 ± 25.35
Cycle 9 Day 189.13 ± 56.58—
Cycle 17 Day 188.84 ± 63.62—
SecondarySerum Tislelizumab Concentrations at Specified Timepoints

The timepoints are defined as predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion).

Time frame:
Day 1 of Cycles 1, 2, 5, 9, and 17 (each cycle is 21 days)
Reported as:
Geometric mean · μg/mL
Serum Tislelizumab Concentrations at Specified Timepoints
μg/mLCohort 1 (Predose)Cohort 1 (Postdose)Cohort 2 (Predose)Cohort 2 (Postdose)
Cycle 1 Day 10.00 ± NA77.38 ± 21.780.00 ± NA84.24 ± 18.19
Cycle 2 Day 117.86 ± 35.69—20.03 ± 36.62—
Cycle 5 Day 136.66 ± 44.97113.80 ± 24.6841.51 ± 42.89128.48 ± 24.06
Cycle 9 Day 142.84 ± 46.50—56.78 ± 28.55—
Cycle 17 Day 145.16 ± 55.71—56.25 ± 21.56—
SecondaryNumber of Participants Who Developed Positive Anti-drug Antibodies (ADAs) to Ociperlimab

Number and percentage of participants who developed detectable ADAs to ociperlimab during the treatment period.

Time frame:
Samples for ADA analysis were collected predose on Day 1 of Cycles 1, 2, 5, 9 and 17, and at the Safety Follow-up Visit (30 days after last dose) up to the immunogenicity data cut-off date of June 1, 2023 (approximately 21 months).
Reported as:
Count of participants · Participants
Number of Participants Who Developed Positive Anti-drug Antibodies (ADAs) to Ociperlimab
ParticipantsCohort 1: Ociperlimab + Tislelizumab
Number of Participants Who Developed Positive Anti-drug Antibodies (ADAs) to Ociperlimab0
SecondaryNumber of Participants Who Developed Anti-drug Antibodies (ADAs) to Tislelizumab

Number and percentage of participants who developed detectable ADAs during the treatment period.

Time frame:
Samples for ADA analysis were collected predose on Day 1 of Cycles 1, 2, 5, 9 and 17, and at the Safety Follow-up Visit (30 days after last dose), up to the immunogenicity data cut-off date of June 1, 2023 (approximately 21 months).
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-drug Antibodies (ADAs) to Tislelizumab
ParticipantsCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Number of Participants Who Developed Anti-drug Antibodies (ADAs) to Tislelizumab197

Adverse events

Collected over All-cause mortality: From randomization through the end of study; up to 24.5 months. Adverse events: From the first dose to 30 days after the last dose; maximum treatment exposure was 23.5 months.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Ociperlimab + Tislelizumab79/138 (57.2%)61/138 (44.2%)128/138 (92.8%)
Cohort 2: Tislelizumab19/40 (47.5%)17/40 (42.5%)37/40 (92.5%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
Urinary tract infectionInfections and infestations11/1382/40
COVID-19Infections and infestations1/1383/40
HydronephrosisRenal and urinary disorders4/1383/40
IleusGastrointestinal disorders3/1382/40
PyrexiaGeneral disorders5/1382/40
AnaemiaBlood and lymphatic system disorders4/1380/40
Multiple organ dysfunction syndromeGeneral disorders4/1380/40
Pleural effusionRespiratory, thoracic and mediastinal disorders4/1380/40
Gastrointestinal haemorrhageGastrointestinal disorders0/1381/40
Large intestinal obstructionGastrointestinal disorders0/1381/40
Most frequent other events
Showing 10 of 72
Most frequent other events
EventCohort 1: Ociperlimab + TislelizumabCohort 2: Tislelizumab
AnaemiaBlood and lymphatic system disorders48/13815/40
Urinary tract infectionInfections and infestations16/13810/40
HypothyroidismEndocrine disorders27/1388/40
Decreased appetiteMetabolism and nutrition disorders15/1388/40
HypokalaemiaMetabolism and nutrition disorders20/1388/40
NauseaGastrointestinal disorders27/1386/40
PyrexiaGeneral disorders27/1387/40
HypoalbuminaemiaMetabolism and nutrition disorders25/1384/40
Aspartate aminotransferase increasedInvestigations24/1385/40
Abdominal painGastrointestinal disorders9/1386/40

Baseline characteristics

The Safety Analysis Set is defined as all participants who received \>= 1 dose of any study drug for each cohort.

Age, Continuous
Age, Continuous(years)Cohort 1: Ociperlimab + TislelizumabCohort 2: TislelizumabTotal
Mean52.7 ± 10.2851.2 ± 9.7452.3 ± 10.15
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Cohort 1: Ociperlimab + TislelizumabCohort 2: TislelizumabTotal
Female13840178
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Ociperlimab + TislelizumabCohort 2: TislelizumabTotal
Asian11737154
White21324
Region of Enrollment
Region of Enrollment(participants)Cohort 1: Ociperlimab + TislelizumabCohort 2: TislelizumabTotal
China711788
South Korea30838
Taiwan10616
Ukraine10010
Russia8311
Thailand6612
Bulgaria202
Poland101
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(Participants)Cohort 1: Ociperlimab + TislelizumabCohort 2: TislelizumabTotal
0531669
18524109
Programmed Death-Ligand 1 (PD-L1) Expression
Programmed Death-Ligand 1 (PD-L1) Expression(Participants)Cohort 1: Ociperlimab + TislelizumabCohort 2: TislelizumabTotal
PD-L1 Score >= 5%8420104
PD-L1 Score < 5%532073
Not Evaluable101
08

Study locations

68 sites
  • "Mhat uni hospital" ood
    Panagyurishte, 4500, Bulgaria
  • Complex Oncology Center Rousse Eood
    Ruse, 7002, Bulgaria
  • Medical center nadezhda clinical eood
    Sofia, 13330, Bulgaria
  • Acibadem city clinic tokuda umhat ead, department of medical oncology
    Sofia, 1407, Bulgaria
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui 230088, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing 400030, China
  • Southwest Hospital
    Chongqing, Chongqing 400038, China
  • Gansu Provincial Hospital
    Lanzhou, Gansu 730000, China
  • Sun yat-sen memorial hospital, sun yat-sen university (south)
    Guanzhou, Guangdong 510275, China
  • The Tumor Hospital Affiliated to Guangxi Medical University
    Nanning, Guangxi 530021, China
  • Hainan Cancer Hospital
    Haikou, Hainan 570312, China
  • Henan Cancer Hospital - Oncology
    Zhengzhou, Henan 450008, China
  • Hubei Cancer Hospital - Oncology
    Wuhan, Hubei 400037, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hunan Cancer Hospital - GCP Office
    Changsha, Hunan 410013, China
  • Xuzhou Cancer Hospital
    Xuzhou, Jiangsu 221005, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Jilin Guowen Hospital
    Jilin, Jilin 136100, China
  • Liaoning Cancer Hospital & Institute - Medical Oncology - Oncology
    Shenyang, Liaoning 110017, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Obstetrics and Gynecology Hospital of Fudan University
    Shanghai, Shanghai, China
  • Second Hospital Of Shanxi Medical University
    Taiyuan, Shanxi 030013, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710000, China
  • Tianjin Medical University Cancer institute & Hospital
    Tianjin, Tianjin 300070, China
  • Affiliated Cancer Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830000, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Beijing Cancer Hosptial
    Beijing, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, China
  • Linyi Cancer Hospital
    Shandong, 276002, China
  • The First Affiliated Hospital of Xiamen University - Oncology
    Xiamen, 361005, China
  • Keimyung University Dongsan Medical Center
    Daegu, 42601, Korea, Republic of
  • Kyemyung University Dongsan Hospital
    Daegu, Korea, Republic of
  • Ajou University Hospital
    Gyeonggi-do, Korea, Republic of
  • National Cancer Center
    Gyeonggi-do, Korea, Republic of
  • Seoul National University Bundang Hospital
    Gyeonggi-do, Korea, Republic of
  • Asan Medical Center
    Seoul, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, Korea, Republic of
  • Korea Institute of Radiological & Medical Sciences
    Seoul, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, Korea, Republic of
  • Szpitale Pomorskie Spółka z ograniczoną odpowiedzialnością
    Gdynia, Poland
  • Przychodnia lekarska komed
    Konin, 62-500, Poland
  • State healthcare institution oncologic dispensary no. 2 - health department of krasnodar region
    Krasnodar, Krasnodar Krai 350015, Russian Federation
  • Fsbi of higher education"ogarev mordovia state university"
    Saransk, Mordovia Republic 430005, Russian Federation
  • Oncological Scientific Center LLC
    Pesochny, Saint Petersburg 197758, Russian Federation
  • Sbhi of stavropol region "pyatigorsk interdistrict oncologic dispensary"
    Pyatigorsk, Stavropol Region, Russian Federation
  • Arkhangelsk regional clinical oncological dispensary
    Arkhangel'sk, Russian Federation
  • State budgetary healthcare institution-chelyabinsk regional clinical center of oncology and nuclear
    Chelyabinsk, 454087, Russian Federation
  • Chi Mei Hospital, Liouying
    Tainan, Taiwan
  • Linkou Chang Gung Memorial Hospital
    Tainan, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • Mackay Memorial Hospital
    Taipei, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
  • Siriraj Hospital
    Bangkok Noi, Bangkok 10700, Thailand
  • Songklanagarind Hospital, Prince of Songkla University
    Hat Yai, Thailand
  • Srinagarind Hospital (Khon Kaen University)
    Khon Kaen, 40002, Thailand
  • Phramongkutklao Hospital
    Ratchathewi, 10400, Thailand
  • Public Non-Profit Institution "Precarpathian Oncology Center Of Ivano-Frankivsk Regional Council"
    Ivano-Frankivsk Oblast, Ivano-Frankivsk 00000, Ukraine
  • Medical and diagnostic center of private enterprise private production company "acinus"
    Kirovograd, Kirovohradska Oblast 25006, Ukraine
  • Communal Non-Profit Enterprise Of Sumy Regional Council Sumy Regional Clinical Oncological Dispensar
    Sumy, Sumska Oblast 40022, Ukraine
  • National Cancer Institute
    Kiev, 3022, Ukraine
  • Medical center of llc oncolife
    Kropyvnytskyi, 25006, Ukraine
  • Volyn Regional Medical Center Of Oncology
    Luts'k, 03322, Ukraine
09

References and documents

Publications

  • Wu L, Wang PH, Hsiao SY, et al. AdvanTIG-202: A phase 2 study investigating anti-T cell immunoglobulin and ITIM domain monoclonal antibody ociperlimab plus tislelizumab in patients with previously treated recurrent or metastatic cervical cancer (333). Gynecol Oncol. 2022;166:S172. doi:10.1016/S0090-8258(22)01555-4

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jun 2022, 16 months.

Results were first posted in Apr 2025, 2 years 10 months after primary completion.

Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's 16 months is below that.

Counting every sponsor, half of 204 studies reached it within 42 months; a quarter within 29 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2020
First posted
Jan 5, 2021
StartActual
Feb 15, 2021
Primary completionActual
Jun 16, 2022
CompletionActual
Aug 31, 2023
Results first posted
Apr 27, 2025
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04693234
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jan 5, 2021
Start date
Feb 15, 2021
Primary completion
Jun 16, 2022
Completion
Aug 31, 2023
Results posted
Apr 27, 2025
Last update
Apr 27, 2025

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion